Land: Irland
Språk: engelska
Källa: HPRA (Health Products Regulatory Authority)
ONDANSETRON HYDROCHLORIDE
Novartis Pharmaceuticals UK Ltd
A04AA01
ONDANSETRON HYDROCHLORIDE
4 Milligram
Film Coated Tablet
Product subject to prescription which may not be renewed (A)
Serotonin (5HT3) antagonists
Authorised
2016-01-22
PACKAGE LEAFLET: INFORMATION FOR THE USER ZOFRAN® 4 MG OR 8 MG FILM COATED TABLETS ONDANSETRON READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Keep this leaflet. You may need to read it again. If you have any further questions about your illness or your medicine, ask your doctor, nurse or pharmacist. This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. If you get any side effects, talk to your doctor, nurse or pharmacist. This includes any possible side effects not listed in this leaflet. WHAT IS IN THIS LEAFLET: 1 What Zofran tablets are and what they are used for 2 What you need to know before you take Zofran tablets 3 How to take Zofran tablets 4 Possible side effects 5 How to store Zofran tablets 6 Contents of the pack and other information 1 WHAT ZOFRAN TABLETS ARE AND WHAT THEY ARE USED FOR Zofran tablets contain a medicine called ondansetron. This belongs to a group of medicines called anti-emetics. Zofran tablets are used for: preventing nausea and vomiting caused by chemotherapy [http://www.netdoctor.co.uk/medicines/effect/cancer.shtml]or radiotherapy for cancer [http://www.netdoctor.co.uk/cancer/index.shtml]in ADULTS preventing nausea and vomiting after surgery in ADULTS preventing nausea and vomiting caused by chemotherapy [http://www.netdoctor.co.uk/medicines/effect/cancer.shtml]for cancer in CHILDREN AND ADOLESCENTS aged 6 months to 17 years Ask your doctor, nurse or pharmacis Läs hela dokumentet
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Zofran 4mg Film-coated Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains ondansetron 4mg as ondansetron hydrochloride dihydrate. Excipients: Contains Lactose Anhydrous 81.875mg For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Film-coated tablet. Yellow, oval, biconvex tablets "GXET3" on one face and plain on the other face. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS ADULTS Zofran tablets are indicated for the management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy. Zofran tablets are also indicated for the prevention of post-operative nausea and vomiting. PAEDIATRIC POPULATION Orally administered Zofran is indicated for the management of nausea and vomiting induced by cytotoxic chemotherapy for children and adolescents aged from 6 months to 17 years. No studies have been conducted in children on the use of orally administered Zofran in the prevention or treatment of post-operative nausea and vomiting; IV injection may be recommended for this purpose. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Zofran is also available for parenteral and rectal use to allow the route of administration and dosing to be flexible. CHEMOTHERAPY AND RADIOTHERAPY INDUCED NAUSEA AND VOMITING (CINV AND RINV) The emetogenic potential of cancer treatment varies according to the doses and combinations of chemotherapy and radiotherapy regimens used. The selection of dose regimen should be determined by the severity of the emetogenic challenge. _CINV AND RINV IN ADULTS:_ The recommended oral dose is 8mg taken 1-2 hours before chemotherapy or radiation treatment, followed by 8mg orally every 12 hours for a maximum of 5 days. _Highly emetogenic chemotherapy:_ For patients receiving highly emetogenic chemotherapy a single oral dose of up to 24 mg ondansetron taken together with 12 mg oral dexamethasone sodium phosphate, 1 to 2 hours before chemotherapy, may be used. After the first 24 hours, oral treatme Läs hela dokumentet